Loss of LMOD1 Impairs Smooth Muscle Cytocontractility and Causes
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated. -
DF6216-CSRP1 Antibody
Affinity Biosciences website:www.affbiotech.com order:[email protected] CSRP1 Antibody Cat.#: DF6216 Concn.: 1mg/ml Mol.Wt.: 21kDa Size: 50ul,100ul,200ul Source: Rabbit Clonality: Polyclonal Application: WB 1:500-1:2000, IHC 1:50-1:200, ELISA(peptide) 1:20000-1:40000 *The optimal dilutions should be determined by the end user. Reactivity: Human,Mouse,Rat Purification: The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific). Specificity: CSRP1 Antibody detects endogenous levels of total CSRP1. Immunogen: A synthesized peptide derived from human CSRP1, corresponding to a region within the internal amino acids. Uniprot: P21291 Description: This gene encodes a member of the cysteine-rich protein (CSRP) family. This gene family includes a group of LIM domain proteins, which may be involved in regulatory processes important for development and cellular differentiation. The LIM/double zinc-finger motif found in this gene product occurs in proteins with critical functions in gene regulation, cell growth, and somatic differentiation. Alternatively spliced transcript variants have been described. [provided by RefSeq, Aug 2010] Storage Condition and Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM Buffer: NaCl, 0.02% sodium azide and 50% glycerol.Store at -20 °C.Stable for 12 months from date of receipt. Western blot analysis of CSRP1 expression in Mouse lung lysate 1 / 2 Affinity Biosciences website:www.affbiotech.com order:[email protected] DF6216 at 1/100 staining Mouse brain tissue by IHC-P. The sample was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. -
Screening and Identification of Hub Genes in Bladder Cancer by Bioinformatics Analysis and KIF11 Is a Potential Prognostic Biomarker
ONCOLOGY LETTERS 21: 205, 2021 Screening and identification of hub genes in bladder cancer by bioinformatics analysis and KIF11 is a potential prognostic biomarker XIAO‑CONG MO1,2*, ZI‑TONG ZHANG1,3*, MENG‑JIA SONG1,2, ZI‑QI ZHOU1,2, JIAN‑XIONG ZENG1,2, YU‑FEI DU1,2, FENG‑ZE SUN1,2, JIE‑YING YANG1,2, JUN‑YI HE1,2, YUE HUANG1,2, JIAN‑CHUAN XIA1,2 and DE‑SHENG WENG1,2 1State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine; 2Department of Biotherapy, Sun Yat‑Sen University Cancer Center; 3Department of Radiation Oncology, Sun Yat‑Sen University Cancer Center, Guangzhou, Guangdong 510060, P.R. China Received July 31, 2020; Accepted December 18, 2020 DOI: 10.3892/ol.2021.12466 Abstract. Bladder cancer (BC) is the ninth most common immunohistochemistry and western blotting. In summary, lethal malignancy worldwide. Great efforts have been devoted KIF11 was significantly upregulated in BC and might act as to clarify the pathogenesis of BC, but the underlying molecular a potential prognostic biomarker. The present identification mechanisms remain unclear. To screen for the genes associated of DEGs and hub genes in BC may provide novel insight for with the progression and carcinogenesis of BC, three datasets investigating the molecular mechanisms of BC. were obtained from the Gene Expression Omnibus. A total of 37 tumor and 16 non‑cancerous samples were analyzed to Introduction identify differentially expressed genes (DEGs). Subsequently, 141 genes were identified, including 55 upregulated and Bladder cancer (BC) is the ninth most common malignancy 86 downregulated genes. The protein‑protein interaction worldwide with substantial morbidity and mortality. -
Aneuploidy: Using Genetic Instability to Preserve a Haploid Genome?
Health Science Campus FINAL APPROVAL OF DISSERTATION Doctor of Philosophy in Biomedical Science (Cancer Biology) Aneuploidy: Using genetic instability to preserve a haploid genome? Submitted by: Ramona Ramdath In partial fulfillment of the requirements for the degree of Doctor of Philosophy in Biomedical Science Examination Committee Signature/Date Major Advisor: David Allison, M.D., Ph.D. Academic James Trempe, Ph.D. Advisory Committee: David Giovanucci, Ph.D. Randall Ruch, Ph.D. Ronald Mellgren, Ph.D. Senior Associate Dean College of Graduate Studies Michael S. Bisesi, Ph.D. Date of Defense: April 10, 2009 Aneuploidy: Using genetic instability to preserve a haploid genome? Ramona Ramdath University of Toledo, Health Science Campus 2009 Dedication I dedicate this dissertation to my grandfather who died of lung cancer two years ago, but who always instilled in us the value and importance of education. And to my mom and sister, both of whom have been pillars of support and stimulating conversations. To my sister, Rehanna, especially- I hope this inspires you to achieve all that you want to in life, academically and otherwise. ii Acknowledgements As we go through these academic journeys, there are so many along the way that make an impact not only on our work, but on our lives as well, and I would like to say a heartfelt thank you to all of those people: My Committee members- Dr. James Trempe, Dr. David Giovanucchi, Dr. Ronald Mellgren and Dr. Randall Ruch for their guidance, suggestions, support and confidence in me. My major advisor- Dr. David Allison, for his constructive criticism and positive reinforcement. -
CRIP1 Antibody (C-Term) Affinity Purified Rabbit Polyclonal Antibody (Pab) Catalog # Ap4707b
10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 CRIP1 Antibody (C-term) Affinity Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP4707b Specification CRIP1 Antibody (C-term) - Product Information Application WB, IHC-P, FC,E Primary Accession P50238 Other Accession P63255, P63254, Q56K04 Reactivity Human Predicted Bovine, Mouse, Rat Host Rabbit Clonality Polyclonal Isotype Rabbit Ig Calculated MW 8533 Antigen Region 48-77 CRIP1 Antibody (C-term) - Additional Information Gene ID 1396 All lanes : Anti-CRIP1 Antibody (C-term) at 1:8000 dilution Lane 1: T47D whole cell Other Names lysate Lane 2: THP-1 whole cell lysate Cysteine-rich protein 1, CRP-1, Cysteine-rich Lysates/proteins at 20 µg per lane. heart protein, CRHP, hCRHP, Cysteine-rich Secondary Goat Anti-Rabbit IgG, (H+L), intestinal protein, CRIP, CRIP1, CRIP, CRP1 Peroxidase conjugated at 1/10000 dilution. Predicted band size : 9 kDa Blocking/Dilution Target/Specificity buffer: 5% NFDM/TBST. This CRIP1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 48-77 amino acids from the C-terminal region of human CRIP1. Dilution WB~~1:8000 IHC-P~~1:50~100 FC~~1:10~50 Format Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity CRIP1 Antibody (C-term) (Cat. #AP4707b) purification. IHC analysis in formalin fixed and paraffin embedded bladder carcinoma followed by Storage peroxidase conjugation of the secondary Maintain refrigerated at 2-8°C for up to 2 antibody and DAB staining. -
Blood-Based Molecular Biomarker Signatures in Alzheimer's
bioRxiv preprint doi: https://doi.org/10.1101/481879; this version posted December 31, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Article Blood-based molecular biomarker signatures in Alzheimer’s disease: insights from systems biomedicine perspective Tania Islam 1,#, Md. Rezanur Rahman 2,#,*, Md. Shahjaman3, Toyfiquz Zaman2, Md. Rezaul Karim2, Julian M.W. Quinn4, R.M. Damian Holsinger5,6, and Mohammad Ali Moni 6,* 1Department of Biotechnology and Genetic Engineering, Islamic University, Kushtia, Bangladesh; [email protected](T.I.). 2 Department of Biochemistry and Biotechnology, School of Biomedical Science, Khwaja Yunus Ali University, Sirajgonj, Bangladesh; [email protected](M.R.R.). 3 Department of Statistics, Begum Rokeya University, Rangpur, Bangladesh; [email protected] (M.S.). 4 Bone Biology Division, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia;[email protected](J.W.W.Q.). 5 Laboratory of Molecular Neuroscience and Dementia, Brain and Mind Centre, The University of Sydney, Camperdown, NSW, Australia; [email protected] (R.M.D.H.). 6 Discipline of Biomedical Science, School of Medical Sciences, The University of Sydney, Sydney, NSW, Australia; [email protected] (M.A.M.). #These two authors have made an equal contribution and hold joint first authorship for this work. * Correspondence: [email protected] (M.R.R.) or [email protected] (M.A.M.). Abstract: Background and objectives: Alzheimer’s disease (AD) is the progressive neurodegenerative disease characterized by dementia, but no peripheral biomarkers available yet that can detect the AD. -
Anti-CLK2 Antibody (ARG66787)
Product datasheet [email protected] ARG66787 Package: 100 μg anti-CLK2 antibody Store at: -20°C Summary Product Description Rabbit Polyclonal antibody recognizes CLK2 Tested Reactivity Hu Tested Application IHC-P, WB Host Rabbit Clonality Polyclonal Isotype IgG Target Name CLK2 Antigen Species Human Immunogen Synthetic peptide between aa. 1-50 of Human CLK2. Conjugation Un-conjugated Alternate Names CDC-like kinase 2; Dual specificity protein kinase CLK2; EC 2.7.12.1 Application Instructions Application table Application Dilution IHC-P 1:100 - 1:300 WB 1:500 - 1:2000 Application Note * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. Positive Control COLO205 and A549 Calculated Mw 60 kDa Observed Size ~ 60 kDa Properties Form Liquid Purification Affinity purification with immunogen. Buffer PBS, 0.02% Sodium azide, 50% Glycerol and 0.5% BSA. Preservative 0.02% Sodium azide Stabilizer 50% Glycerol and 0.5% BSA Concentration 1 mg/ml Storage instruction For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use. www.arigobio.com 1/3 Note For laboratory research only, not for drug, diagnostic or other use. Bioinformation Gene Symbol CLK2 Gene Full Name CDC-like kinase 2 Background This gene encodes a dual specificity protein kinase that phosphorylates serine/threonine and tyrosine- containing substrates. -
Snipa Snpcard
SNiPAcard Block annotations Block info genomic range chr6:29,970,960-30,792,117 block size 821,158 bp variant count 107 variants Basic features Conservation/deleteriousness Linked genes μ = -0.141 [-3.802 – ABCF1 , AL662797.1 , AL662800.2 , ATAT1 , C6orf136 , DHX16 , FLOT1 4.141] , GNL1 , HCG17 , HCG18 , HCG19P , HCG20 , HCG4P3 , HLA-J , HLA-L , HLA-N , IER3 , LINC00243 , MDC1 , MICC , MRPS18B , NRM , PAIP1P1 , PPP1R10 , PPP1R11 , PPP1R18 , PTMAP1 , RN7SL353P , phyloP gene(s) hit or close-by RNF39 , RPP21 , SUCLA2P1 , TRIM10 , TRIM15 , TRIM26 , TRIM26BP , TRIM31 , TRIM31-AS1 , TRIM39 , TRIM39-RPP21 , TRIM40 , TUBB , UBQLN1P1 , XXbac-BPG252P9.10 , XXbac-BPG252P9.9 , XXbac-BPG283O16.9 , Y_RNA , ZNRD1 , ZNRD1-AS1 , ZNRD1-AS1_3 μ = 0.130 [0 – 1] BTN3A2 , BTN3A3 , C2 , CCHCR1 , CFB , FLOT1 , GABBR1 , HCG17 , HCG20 , HCG22 , HCP5 , HIST1H3I , HLA-A , HLA-B , HLA-C , HLA-F- AS1 , HLA-G , HLA-H , HLA-J , HLA-K , HLA-L , HLA-U , HLA-V , IER3 phastCons eQTL gene(s) , LINC00243 , MICB , NDUFS1 , OR5V1 , PPP1R18 , PSORS1C1 , RNF39 , RPP21 , TMEM154 , TRIM26BP , TRIM31 , TRIM39-RPP21 , VARS2 , WASF5P , ZFP57 , ZNRD1 , ZNRD1-AS1_3 μ = -0.462 [-9.98 – 5.1] ATAT1 , ATAT1 , ATAT1 , ATAT1 , ATAT1 , ATAT1 , ATAT1 , DDR1 , DDR1 , DDR1 , DDR1 , DDR1 , DDR1 , DDR1 , FLOT1 , FLOT1 , FLOT1 , FLOT1 , FLOT1 , FLOT1 , FLOT1 , FLOT1 , HCG19P , HCG19P potentially regulated , HCG19P , HCG19P , HCG19P , HCG19P , HCG19P , NRM , NRM , GERP++ gene(s) NRM , NRM , NRM , NRM , NRM , RNF39 , RNF39 , RNF39 , RNF39 , RNF39 , RNF39 , RNF39 , RNF39 , TRIM26 , TRIM26 , TRIM26 -
Identification of Differentially Expressed Genes in Human Bladder Cancer Through Genome-Wide Gene Expression Profiling
521-531 24/7/06 18:28 Page 521 ONCOLOGY REPORTS 16: 521-531, 2006 521 Identification of differentially expressed genes in human bladder cancer through genome-wide gene expression profiling KAZUMORI KAWAKAMI1,3, HIDEKI ENOKIDA1, TOKUSHI TACHIWADA1, TAKENARI GOTANDA1, KENGO TSUNEYOSHI1, HIROYUKI KUBO1, KENRYU NISHIYAMA1, MASAKI TAKIGUCHI2, MASAYUKI NAKAGAWA1 and NAOHIKO SEKI3 1Department of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 890-8520; Departments of 2Biochemistry and Genetics, and 3Functional Genomics, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan Received February 15, 2006; Accepted April 27, 2006 Abstract. Large-scale gene expression profiling is an effective CKS2 gene not only as a potential biomarker for diagnosing, strategy for understanding the progression of bladder cancer but also for staging human BC. This is the first report (BC). The aim of this study was to identify genes that are demonstrating that CKS2 expression is strongly correlated expressed differently in the course of BC progression and to with the progression of human BC. establish new biomarkers for BC. Specimens from 21 patients with pathologically confirmed superficial (n=10) or Introduction invasive (n=11) BC and 4 normal bladder samples were studied; samples from 14 of the 21 BC samples were subjected Bladder cancer (BC) is among the 5 most common to microarray analysis. The validity of the microarray results malignancies worldwide, and the 2nd most common tumor of was verified by real-time RT-PCR. Of the 136 up-regulated the genitourinary tract and the 2nd most common cause of genes we detected, 21 were present in all 14 BCs examined death in patients with cancer of the urinary tract (1-7). -
Role and Regulation of the P53-Homolog P73 in the Transformation of Normal Human Fibroblasts
Role and regulation of the p53-homolog p73 in the transformation of normal human fibroblasts Dissertation zur Erlangung des naturwissenschaftlichen Doktorgrades der Bayerischen Julius-Maximilians-Universität Würzburg vorgelegt von Lars Hofmann aus Aschaffenburg Würzburg 2007 Eingereicht am Mitglieder der Promotionskommission: Vorsitzender: Prof. Dr. Dr. Martin J. Müller Gutachter: Prof. Dr. Michael P. Schön Gutachter : Prof. Dr. Georg Krohne Tag des Promotionskolloquiums: Doktorurkunde ausgehändigt am Erklärung Hiermit erkläre ich, dass ich die vorliegende Arbeit selbständig angefertigt und keine anderen als die angegebenen Hilfsmittel und Quellen verwendet habe. Diese Arbeit wurde weder in gleicher noch in ähnlicher Form in einem anderen Prüfungsverfahren vorgelegt. Ich habe früher, außer den mit dem Zulassungsgesuch urkundlichen Graden, keine weiteren akademischen Grade erworben und zu erwerben gesucht. Würzburg, Lars Hofmann Content SUMMARY ................................................................................................................ IV ZUSAMMENFASSUNG ............................................................................................. V 1. INTRODUCTION ................................................................................................. 1 1.1. Molecular basics of cancer .......................................................................................... 1 1.2. Early research on tumorigenesis ................................................................................. 3 1.3. Developing -
A Sonic Hedgehog Signaling Domain in the Arterial Adventitia Supports Resident Sca1؉ Smooth Muscle Progenitor Cells
A sonic hedgehog signaling domain in the arterial adventitia supports resident Sca1؉ smooth muscle progenitor cells Jenna N. Passman*†, Xiu Rong Dong*‡, San-Pin Wu*§, Colin T. Maguire*‡, Kelly A. Hogan¶, Victoria L. Bautch*†¶, and Mark W. Majesky*†‡ʈ** *Carolina Cardiovascular Biology Center, Departments of ‡Medicine, ʈGenetics, and ¶Biology, and †Curriculum in Genetics and Molecular Biology, University of North Carolina, Chapel Hill, NC 27599 Edited by Eric N. Olson, University of Texas Southwestern Medical Center, Dallas, TX, and approved April 22, 2008 (received for review December 6, 2007) We characterize a sonic hedgehog (Shh) signaling domain re- interstitial fibroblasts (13, 14), and promotes endothelial cell stricted to the adventitial layer of artery wall that supports resi- chemotaxis and tube formation (17, 18). Therefore, Shh plays dent Sca1-positive vascular progenitor cells (AdvSca1). Using important roles in cell–cell communication during vascular patched-1 (Ptc1lacZ) and patched-2 (Ptc2lacZ) reporter mice, adven- development and adult wound repair. titial Shh signaling activity was first detected at embryonic day (E) Hedgehog (Hh) proteins signal by binding to patched-1 (Ptc1) 15.5, reached the highest levels between postnatal day 1 (P1) and or patched-2 (Ptc2) receptors and cdo/boc accessory proteins at P10, was diminished in adult vessels, and colocalized with a the cell surface, resulting in derepression of smoothened (smo) circumferential ring of Shh protein deposited between the media (19). Ptc proteins are 12-transmembrane domain receptors that ؊/؊ and adventitia. In Shh mice, AdvSca1 cells normally found at the are structurally related to the resistance-nodulation-division aortic root were either absent or greatly diminished in number. -
Biological Functions of CDK5 and Potential CDK5 Targeted Clinical Treatments
www.impactjournals.com/oncotarget/ Oncotarget, 2017, Vol. 8, (No. 10), pp: 17373-17382 Review Biological functions of CDK5 and potential CDK5 targeted clinical treatments Alison Shupp1, Mathew C. Casimiro2 and Richard G. Pestell2 1 Departments of Cancer Biology, Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA 2 Pennsylvania Cancer and Regenerative Medicine Research Center, Baruch S Blumberg Institute, Doylestown, PA, USA Correspondence to: Richard G. Pestell, email: [email protected] Keywords: CDK5, cancer Received: October 22, 2016 Accepted: December 17, 2016 Published: January 06, 2017 ABSTRACT Cyclin dependent kinases are proline-directed serine/threonine protein kinases that are traditionally activated upon association with a regulatory subunit. For most CDKs, activation by a cyclin occurs through association and phosphorylation of the CDK’s T-loop. CDK5 is unusual because it is not typically activated upon binding with a cyclin and does not require T-loop phosphorylation for activation, even though it has high amino acid sequence homology with other CDKs. While it was previously thought that CDK5 only interacted with p35 or p39 and their cleaved counterparts, Recent evidence suggests that CDK5 can interact with certain cylins, amongst other proteins, which modulate CDK5 activity levels. This review discusses recent findings of molecular interactions that regulate CDK5 activity and CDK5 associated pathways that are implicated in various diseases. Also covered herein is the growing body of evidence for CDK5 in contributing to the onset and progression of tumorigenesis. INTRODUCTION the missing 32 amino acids are encoded by exon 6 [9]. Although these two groups reported conflicting data, it has Cyclin dependent kinases are proline-directed been suggested that the identified isoforms are in fact the serine/threonine protein kinases that are traditionally same protein and the variances in their data are due to activated upon association with a regulatory subunit.